Benefit at a glance
In robust, preclinical studies and murine models, our BRiTE technology has shown:
- Potential best-in-class efficacy
- High specificity against tumor antigen-expressing glioma cells
- Dose-response heterogeneic efficacy against multiple patient-derived malignant glioma cell lines
- Non-toxicity
- “Bystander” tumor cell lysis
- Efficacy against heterogeneous tumors